XOMA Royalty Corp
XOMA
查看詳細走勢圖
30.190USD
-0.340-1.11%
收盤 03/30, 16:00（美東）報價延遲15分鐘
360.84M總市值
19.70本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-1.11%
5天
+5.15%
1月
+18.25%
6月
-18.84%
今年開始到現在
+13.54%
1年
+48.50%
查看詳細走勢圖
TradingKey XOMA Royalty Corp股票評分
單位: USD 更新時間: 2026-03-27操作建議
XOMA Royalty Corp當前公司基本面數據相對非常健康，最新ESG揭露屬於行業領先水平。增長潛力較大。當前估值合理，在媒體與出版行業排名26/80位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為65.75。中期看，股價處於上升通道。近一個月，市場表現很強，技術面和基本面綜合得分較高，很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
XOMA Royalty Corp評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
XOMA Royalty Corp亮點
亮點風險
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
業績高增長
公司營業收入穩步增長，連續3年增長996.03%
業績增長期
公司處於發展階段，最新年度總收入52.15M美元
業績轉盈
公司業績轉盈，最新年度盈利美元
估值高估
公司最新PE估值19.68，處於3年歷史高位
PRFDX持倉
明星投資者PRFDX持倉，最新持倉921.00股
分析師目標
基於
5
分析師
買入
評級
65.750
目標均價
+115.36%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
XOMA Royalty Corp新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
XOMA Royalty Corp簡介
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
公司代碼XOMA
公司XOMA Royalty Corp
CEOMr. Owen P. Hughes, Jr.
網址https://xoma.com/
相關品種
-0.15%
-2.23%
-0.46%
-4.92%
-1.97%
-1.91%
-0.98%
-4.57%
-3.09%
-1.47%
+0.82%
+2.36%
-2.09%
-4.36%
-2.70%
-0.93%
+0.94%
-1.95%
-4.07%
0.00%熱門品種
246.650
-6.240 (-2.47%)
165.060
-2.460 (-1.47%)
66621.400
+37.350 (+0.06%)
251.665
-21.685 (-7.93%)
2020.700
+20.700 (+1.03%)
355.270
-16.840 (-4.53%)
4510.780
+18.260 (+0.41%)
104.262
+3.653 (+3.63%)
1.146
-0.001 (-0.07%)
159.654
-0.005 (-0.00%)
